SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant attention as community members analyze its resilience amidst geopolitical tensions and supply chain complexities while weighing the impact of its major Small Modular Reactor (SMR) contracts and defense partnerships. Investors are actively discussing the company's long-term transformation, focusing on whether current volatility provides an optimal entry point or signals broader headwinds for its commercial aerospace engine business.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors focus on its role in building decentralized AI infrastructure, with significant community excitement surrounding its potential as a long-term asset akin to early-stage growth plays. Discussions are heavily focused on the project's subnet ecosystem, institutional interest, and the strategy of staking as a means to accumulate value despite broader market volatility.

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's Nasdaq debut has triggered intense debate, with the stock drawing record trading volumes and massive institutional inflows despite significant concerns over its lack of profitability and sky-high valuation. While bullish investors view the company as a transformative leader in space and AI infrastructure, the community remains divided as traders focus on the upcoming options chain launch and the technical implications of its massive market capitalization.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

The Tema Space Innovators ETF ($NASA) is experiencing high volatility as investors navigate the highly anticipated SpaceX IPO and broader sector re-rating. Community members are actively debating whether the current pullback represents a strategic buying opportunity before potential index inclusion or a liquidity-driven flush as capital rotates toward the direct SpaceX listing.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant volatility as investors weigh disappointing monthly sales data against anticipated long-term milestones like J-code reimbursement and potential European market expansion. The community remains deeply divided, with many shareholders dismissing the price drop as algorithmic manipulation and short-term weakness while expressing frustration over management's lack of transparency regarding recent executive departures.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and downward pressure despite reporting strong quarterly revenue, leaving investors divided between those focused on the potential of the Elevidys gene therapy pipeline and those frustrated by a perceived lack of management action on the share price. The community is actively discussing potential leadership transitions, rumors of a strategic reorganization or buyout, and the impact of broader biotech sector headwinds on the symbol's recent performance.

Strategy, Inc. is a Bitcoin Treasury company. The firm has adopted Bitcoin as a primary treasury reserve asset. It uses proceeds from equity and debt financing, as well as cash flows from operations, to strategically accumulate Bitcoin and advocate for its role as digital capital. Its treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. It provides industry AI-powered enterprise analytics software. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy volatility as investors debate the impact of ongoing share dilution and the company's aggressive Bitcoin acquisition strategy amid a broader crypto market downturn. The community remains deeply polarized, with active discussion focusing on the sustainability of the firm's balance sheet, the potential for institutional hedging, and the contrast between Bitcoin-proxy plays and emerging opportunities in the AI and space sectors.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is trending as investors grapple with escalating volatility stemming from the ongoing conflict with Iran and concerns regarding a potential regional ground incursion. The broader market sentiment is reacting to community anxiety over rising energy costs, potential inflation spikes, and the sustainability of the current AI-driven equity valuations.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors weigh potential steel demand from industrial data center builds against ongoing speculation regarding a strategic partnership with POSCO. Community sentiment remains polarized, with some traders monitoring high options volume and potential short squeezes, while others express frustration over management's debt and long-term capital efficiency.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh strong IBSRELA revenue growth and potential clinical pipeline expansion against ongoing concerns regarding the CMS bundling dispute and future profitability milestones. The community is actively debating the company's valuation relative to its peers and speculating on the possibility of an acquisition or strategic partnership as the firm matures into a self-sustaining commercial operation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing

BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M (the "Financing"). Proceeds from the Financing will be used to...

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA Order

BNB Plus Corp. (Nasdaq: BNBX) ('BNB Plus' or the 'Company'), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has successfully completed production of its largest...

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update...

Anthropic’s ‘Mythos’ Triggers Scramble Among Coinbase, Binance: Report

Equity

Large banks and tech organizations have early access to Mythos, while crypto companies still rely on older AI models and internal security technologies.

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea IVT Platform

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has been granted a European patent by the European Patent...

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA from Genetic Medicine Developers

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company') today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has received two new orders for LineaDNA from...

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced the appointment of James Haft as an Independent Director and member of the Boards Nominating Committee, effective as of...

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital...

BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA Order

BNB Plus Corp. (Nasdaq: BNBX) (BNBX or the Company), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an...

BNB Plus Provides BNB Treasury and Operational Updates

BNB Plus Corp. (Nasdaq: BNBX) (BNBX or the Company), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc...

BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Current Price	$0.458
Prev Close	$0.466
Open	$0.478
Dividend Yield	0.00%
50-Day Moving Average	$0.5084
Beta	0.92
Avg. Volume	198,691.64
PE Ratio	-0.01

52-Week High	$7.15
52-Week Low	$0.3535
Market Capitalization	$3.35M
EPS (Annual)	-$134.23
Price to Book	0.21
Revenue Per Employee	$82,189.81

BNBXApplied Dna Sciences Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNBX News